Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 11941556.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We conducted a 12-month longitudinal investigation of the subtype-dependent response of hepatitis B virus (HBV) to lamivudine treatment in 43 consecutive patients with chronic hepatitis B. HBV subtype ayw appears to respond better to lamivudine monotherapy than does HBV subtype adw (P=.005). This might be the reason for the lower incidence of lamivudine-resistant strains observed in persons infected with HBV subtype ayw during follow-up.
Medical subject headings
- Antiviral Agents
- Hepatitis B, Chronic
- Lamivudine